Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"

被引：0
|
作者：
Jiang, Yanfang [1 ]
Zhang, Lei [2 ,3 ]
机构：
[1] First Hosp Jilin Univ, Genet Diag Ctr, Changchun, Peoples R China
[2] Med Res Ctr, Key Lab Digital Technol Med Diagnost Zhejiang Prov, Hangzhou, Peoples R China
[3] Nanjing Med Univ, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 09期
关键词：
D O I：
10.1016/j.jtho.2024.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：e43 / e43
页数：1
相关论文
共 50 条
  • [1] A Response to the Letter to the Editor: Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
    Ernst, Sophie M.
    von der Thusen, Jan H.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09)
  • [2] Clinical utility of circulating tumor DNA in patients with advanced KRAS G12C-mutated NSCLC treated with sotorasib
    Ernst, Sophie M.
    van Marion, Ronald
    Atmodimedjo, Peggy N.
    de Jonge, Evert
    Mathijssen, Ron H.
    Paats, Marthe S.
    de Bruijn, Peter
    van Schaik, Ron H. N.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    CANCER RESEARCH, 2023, 83 (07)
  • [3] Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib
    Ernst, Sophie M.
    van Marion, Ronald
    Atmodimedjo, Peggy N.
    de Jonge, Evert
    Mathijssen, Ron H. J.
    Paats, Marthe S.
    de Bruijn, Peter
    Koolen, Stijn L.
    von der Thuesen, Jan H.
    Aerts, Joachim G. J. V.
    Schaik, Ron H. N. van
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : 995 - 1006
  • [4] Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib"
    Ernst, Sophie M.
    von der Thusen, Jan H.
    Dubbink, Hendrikus J.
    Dingemans, Anne-Marie C.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (08) : e29 - e30
  • [5] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
    Barot, Hasti
    Evans, Joanne
    Mohammed, Waleed
    Power, Danielle
    LUNG CANCER, 2022, 165 : S77 - S77
  • [6] Sotorasib in KRAS p.G12C-mutated NSCLC
    Gassa, Asmae
    Oezkan, Filiz
    Bruns, Christiane
    Schmidt, Thomas
    Alakus, Hakan
    ONKOLOGE, 2021, 27 (10): : 1031 - 1032
  • [7] Assessing the safety profile of sotorasib in KRAS G12C-mutated advanced NSCLC
    Reactions Weekly, 2025, 2045 (1) : 6 - 6
  • [8] A Case Series of Patients With Kras KRAS G12C Mutation Treated With Sotorasib - Croatian Experience
    Seiwerth, F.
    Bitar, L.
    Franolic, I. Lukic
    Sajnic, A.
    Jakopovic, M.
    Samarzija, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S426 - S426
  • [9] Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor
    Hong, D. S.
    Bang, Y. -J.
    Barlesi, F.
    Durm, G.
    Falchook, G.
    Govindan, R.
    Dy, G.
    Park, K.
    Strickler, J.
    Burns, T.
    Kim, J.
    Ang, A.
    Lipford, J. R.
    Ngarmchamnanrith, G.
    Anderson, A.
    Li, B. T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S29
  • [10] Impact of Sotorasib and Adagrasib in KRAS G12C-Mutated NSCLC
    Patel, Sandip P.
    ONCOLOGY-NEW YORK, 2023, 37 (12): : 479 - 479
12345